Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting ...

The appointment of Dr. Banerjee culminates Artiva’s efforts to build a seasoned development team with strong expertise in autoimmunity and cell therapy that includes the following recent additions: ...

UnitedHealth Group, Eli Lilly and Company, Walmart, Johnson & Johnson, AbbVie, McKesson, and Boston Scientific are the seven Medical stocks to watch today, according to MarketBeat’s stock screener ...

Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials. Check ...